These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37249223)

  • 1. Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer.
    Morris LGT
    Laryngoscope; 2024 Jan; 134(1):160-165. PubMed ID: 37249223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas.
    Feenstra M; Veltkamp M; van Kuik J; Wiertsema S; Slootweg P; van den Tweel J; de Weger R; Tilanus M
    Tissue Antigens; 1999 Sep; 54(3):235-45. PubMed ID: 10519360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High level of aneuploidy of chromosome 6 by FISH analysis of head and neck squamous cell carcinoma: limited applicability of LOH analysis to define HLA loss.
    Koene GJ; Arts-Hilkes YH; van Dijk AJ; van der Ven KJ; Slootweg PJ; de Weger RA; Tilanus MG
    Hum Immunol; 2004 Dec; 65(12):1455-62. PubMed ID: 15603873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression.
    Feenstra M; Verdaasdonk M; van der Zwan AW; de Weger R; Slootweg P; Tilanus M
    Lab Invest; 2000 Mar; 80(3):405-14. PubMed ID: 10744076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
    Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
    Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.
    Faden DL; Concha-Benavente F; Chakka AB; McMichael EL; Chandran U; Ferris RL
    Head Neck; 2019 Aug; 41(8):2591-2601. PubMed ID: 30828910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma.
    He L; Ren D; Lv G; Mao B; Wu L; Liu X; Gong L; Liu P
    Cancer Med; 2023 Jan; 12(1):852-861. PubMed ID: 35621268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis: limited value of beta2-microglobulin LOH analysis.
    Koene GJ; Arts-Hilkes YH; van der Ven KJ; Rozemuller EH; Slootweg PJ; de Weger RA; Tilanus MG
    Tissue Antigens; 2004 Oct; 64(4):452-61. PubMed ID: 15361122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA traits linked to development of head and neck squamous cell carcinoma affect the progression-free survival of patients.
    Wichmann G; Herchenhahn C; Boehm A; Mozet C; Hofer M; Fischer M; Kolb M; Dietz A
    Oral Oncol; 2017 Jun; 69():115-127. PubMed ID: 28559015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis.
    Sunpaweravong S; Bunbanjerdsuk S; Pongrujikorn T; Naktang C; Sunpaweravong P; Nitiruangjaras A; Dechaphankul T; Jinawath N
    BMC Cancer; 2019 Dec; 19(1):1174. PubMed ID: 31795956
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
    Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
    Montesion M; Murugesan K; Jin DX; Sharaf R; Sanchez N; Guria A; Minker M; Li G; Fisher V; Sokol ES; Pavlick DC; Moore JA; Braly A; Singal G; Fabrizio D; Comment LA; Rizvi NA; Alexander BM; Frampton GM; Hegde PS; Albacker LA
    Cancer Discov; 2021 Feb; 11(2):282-292. PubMed ID: 33127846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic impact of the immune signature in head and neck squamous cell carcinoma.
    Baysal H; Siozopoulou V; Zaryouh H; Hermans C; Lau HW; Lambrechts H; Fransen E; De Pauw I; Jacobs J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; De Waele J; Wouters A
    Front Immunol; 2022; 13():1001161. PubMed ID: 36268020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity.
    Pyke RM; Mellacheruvu D; Dea S; Abbott CW; McDaniel L; Bhave DP; Zhang SV; Levy E; Bartha G; West J; Snyder MP; Chen RO; Boyle SM
    Nat Commun; 2022 Apr; 13(1):1925. PubMed ID: 35414054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.
    Garrido MA; Rodriguez T; Zinchenko S; Maleno I; Ruiz-Cabello F; Concha Á; Olea N; Garrido F; Aptsiauri N
    Immunogenetics; 2018 Nov; 70(10):647-659. PubMed ID: 30145665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer.
    Zhou YF; Xiao Y; Jin X; Di GH; Jiang YZ; Shao ZM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common
    Lim WC; Marques Da Costa ME; Godefroy K; Jacquet E; Gragert L; Rondof W; Marchais A; Nhiri N; Dalfovo D; Viard M; Labaied N; Khan AM; Dessen P; Romanel A; Pasqualini C; Schleiermacher G; Carrington M; Zitvogel L; Scoazec JY; Geoerger B; Salmon J
    Front Immunol; 2023; 14():1265469. PubMed ID: 38318504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.
    Grandis JR; Falkner DM; Melhem MF; Gooding WE; Drenning SD; Morel PA
    Clin Cancer Res; 2000 Jul; 6(7):2794-802. PubMed ID: 10914726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.